Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

/p>

Stock GAAP as

Non-GAAP Compensation Reported

Income Statement

Classifications:

Revenue $3,160 $3,160

Research and development (6,412) $(529) (6,941)

General and administrative (4,368) (818) (5,186)

Depreciation and

amortization (321) (321)

Interest income 1,702 1,702

Interest expense (70) (70)

(Provision for)/benefit

from income taxes (75) (75)

Summary:

Net loss: $(6,384) $ (1,347) $ (7,731)

Net loss per share - basic

and diluted: $(0.28) $(0.06) $(0.34)

Weighted average number

of shares outstanding: 22,412,689 22,412,689

Table 3

Amicus Therapeutics, Inc.

Reconciliation of GAAP to non-GAAP Measures for the Statement of Operations Information for Three Months Ended March 31, 2007

(Unaudited)

(In thousands, except share and per share amounts)

Change

in Fair Pre-

Value of ferred

Warrant Stock Stock

Non- Lia- Accre- Compen- GAAP as

GAAP bility tion sation Reported

Income Statement

Classifications:

Research and

development $(6,795) $- $- $(290
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 More than 5 ... about 1 in 3 seniors will die with Alzheimer’s ... These jaw-dropping figures have shocked many Americans into looking ... help prevent these tragic age-related cognitive disorders. Jonathan Weisman, ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Freeslate, ... solutions, today announced that Lupin Limited, one of India’s ... CM Protégé PharmD System for high throughput ... India, is focused on a wide range of quality, ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... (NYSE: BRL ) today confirmed that its ... the patents listed by GlaxoSmithKline in,connection with its ... that it is the first to file an ... certification for Avodart., Barr filed its ANDA ...
... Feb. 26 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), ... wave of,antibody therapeutics, today announced that five abstracts ... for Cancer Research,(AACR) Annual Meeting held from April ... deliver presentations that will disclose new findings,about its ...
... Caters to Next-Generation Technologies Requiring Massive ... Parallel Processing Capabilities., EMBEDDED WORLD ... it has completed the research and,development of HAL-256, the first ... processors., Igor Pe,er, Acting CEO of Plurality said, "The ...
Cached Biology Technology:Barr Confirms Patent Challenge of Avodart(R) Soft Gelatin Capsules, 0.5mg 2Barr Confirms Patent Challenge of Avodart(R) Soft Gelatin Capsules, 0.5mg 3ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting 2ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting 3Plurality Completes R&D of its HAL-256 Multicore Processor 2
(Date:4/20/2014)... known that people with Down syndrome have a heightened ... they haven,t been able to explain why. Now, ... a connection between the two conditions. , In a ... Genetics , the researchers track the genetic chain of ... to the cellular havoc that occurs in ALL. ...
(Date:4/18/2014)... world population predicted to reach 9 billion by ... that considers human-altered landscapes such as farmland, according ... habitat that supports it might be an increasingly ... three-quarters of the land surface is directly affected ... human-caused impacts such as climate change. But what ...
(Date:4/18/2014)... PROVIDENCE, R.I. [Brown University] Asteroid and comet impacts ... animals on regional or even global scales. But new ... preserve the signatures of ancient life at the time ... Brown geologist Pete Schultz has found fragments of leaves ... a several ancient impacts in Argentina. The material could ...
Breaking Biology News(10 mins):Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3
... new species of monkey flower, created by the union ... of a stream in Scotland. Genetic changes in this attractive yellow-flowered ... rare example of a brand new species that has originated in ... and some crops are thought to have originated in this way, ...
... Pharmaceuticals today announced that research collaborators at the Peter ... established, for the first time, that RNA Polymerase I ... and that its inhibition selectively activates p53 to kill ... the findings show that Cylene,s Pol I inhibitor, CX-5461, ...
... debilitating illnesses one can develop. Currently, the disease afflicts 6.5 ... to between 11 and 16 million, or 1 in 85 ... one to grow forgetful, confused and, eventually, catatonic. Recently approved ... consensus on the underlying mechanism of the disease. "We ...
Cached Biology News:Rare glimpse into the origin of species 2Cancer Cell article shows first evidence for targeting of Pol I as new approach to cancer therapy 2Small molecule may play big role in Alzheimer's disease 2Small molecule may play big role in Alzheimer's disease 3Small molecule may play big role in Alzheimer's disease 4
Agarose-LE, 250 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Request Info...
Limit of detection: <5 pg/ml...
Biology Products: